48Hour Discovery

48Hour Discovery is a biotechnology company focused on advancing peptide discovery and helping partners develop drug leads for unmet medical needs. Based in Edmonton, Alberta, the company combines chemically modified phage display technology with diverse phage libraries, bioinformatics, and advanced screening methods to identify peptides with high affinity and specificity. Its customizable discovery approach supports projects across a range of indications and target types, including protein- and cell-based screening.

The company offers comprehensive discovery services that can take a program from inception through synthesis, validation, and optimization. These services are designed to help clients accelerate peptide drug discovery and make their development programs more efficient. 48Hour Discovery works with partners ranging from emerging startups to global pharmaceutical companies and builds strategic collaborations to advance research. Its work also includes peptide reshaping, with research into converting macrocycles into bicyclic peptides. Led by CEO Rick Finnegan and founder and Chief Scientific Officer Ratmir Derda, 48Hour Discovery positions its technology and expertise as a collaborative resource for drug discovery and precision medicine.